Associated Papers
Allele, Diplotype, and Phenotype Frequency Distribution of CYP2B6, CYP2C19, and CYP2D6 in the Han Population in North China.
Luan Y et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.
Kim JD et al.
Clinical and Translational Science, 2026
Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder.
Kharasch ED et al.
The Journal of Pharmacology and Experimental Therapeutics, 2026
GenoStaR: An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes.
Coulter AJ et al.
Clinical Pharmacology and Therapeutics, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
Whole-Genome Sequencing Reveals a Novel GATA2 Mutation in Lower-Grade Glioma: Bioinformatics Analysis of Functional and Therapeutic Implications.
Handoko et al.
Cancers, 2025
Exploratory Study on Genetic Variants Related to Hydatidosis Susceptibility and Albendazole Pharmacogenetics in the Cusco Region in Peru.
Jaramillo-Valverde L et al.
Frontiers in Bioscience (scholar Edition), 2025
Opportunities and Challenges of Population Pharmacogenomics.
Zhou Y et al.
Annals of Human Genetics, 2025
Influence of pharmacokinetics-related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia.
Kinoshita S et al.
Pcn Reports : Psychiatry and Clinical Neurosciences, 2025
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.
Gerstman MD et al.
British Journal of Anaesthesia, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Pharmacogenetic association of CYP enzymes with therapeutic propofol doses during mechanical ventilation.
Hsiang C et al.
Pharmacogenetics and Genomics, 2025
Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.
Vucicevic K et al.
Cureus, 2025
Molecular Determinants of the Human Retinal Pigment Epithelium Cell Fate and Potential Pharmacogenomic Targets for Precision Medicine.
Zibetti C
International Journal of Molecular Sciences, 2025
CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: implications on efficacy of artemether-lumefantrine.
Angwe MK et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.
Ait Tayeb AEK et al.
Fundamental & Clinical Pharmacology, 2025
Association of CYP2B6 and OPRM1 Genotypes with Methadone Dose Requirements and Serum Concentrations in a Vietnamese Cohorts.
Nguyen QG et al.
Balkan Journal of Medical Genetics : Bjmg, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
Relationships among CYP2B6 genetic variants and serum levels of multiple polychlorinated biphenyls and hydroxylated metabolites in a Japanese population.
Lyu Z et al.
Journal of Hazardous Materials, 2025
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Soeria-Atmadja S et al.
British Journal of Clinical Pharmacology, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.
Taylor J et al.
Southern African Journal of Hiv Medicine, 2025
Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review.
Hamdani S et al.
Frontiers in Genetics, 2025
CYP2B6*6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: Implications on efficacy of artemether-lumefantrine.
Angwe MK et al.
Plos One, 2025
Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB.
Acosta-Monterrosa AA et al.
Frontiers in Pharmacology, 2025
ABCB1 Polymorphism in HIV-Infected Individuals Taking Antiretroviral Drugs.
Singh H et al.
Aids Research and Treatment, 2025
Pharmacogenetics in Tuberculosis-HIV Coinfected Populations: A Systematic Review of Genetic Variants Influencing Antiretroviral and Anti-Tuberculosis Drug Response.
Hardi H et al.
Journal of Multidisciplinary Healthcare, 2025
Post-transplant complications revealed by mycophenolate mofetil related transporters and metabolic enzymes gene polymorphisms in pediatric patients with hematological disorders.
Ji Q et al.
Bmc Cancer, 2024
StarPhase: Comprehensive Phase-Aware Pharmacogenomic Diplotyper for Long-Read Sequencing Data.
Holt JM et al.
Biorxiv : the Preprint Server for Biology, 2024
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis.
Eum S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis.
Chanhom N et al.
Scientific Reports, 2024
Activity Variations of CYP2B6 Determine the Metabolic Stratification of Efavirenz.
Li XY et al.
Chemical Research in Toxicology, 2024
Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report.
Bollinger A et al.
Bmc Anesthesiology, 2024
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.
Mugusi S et al.
British Journal of Clinical Pharmacology, 2024
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment.
Wu X et al.
Pharmaceutics, 2024
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.
Boyarko B et al.
Acs Pharmacology & Translational Science, 2024
Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype.
Eniayewu O et al.
Pharmacogenetics and Genomics, 2024
Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.
Samarasinghe SR et al.
Clinical Pharmacology and Therapeutics, 2024
Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.
Eniayewu O et al.
Clinical Pharmacology and Therapeutics, 2024
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.
Robinson KM et al.
Clinical Pharmacology and Therapeutics, 2024
A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant.
Adeojo LW et al.
Pharmaceutics, 2024
Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.
ElShereef CE et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Uncoupling of Cytochrome P450 2B6 and stimulation of reactive oxygen species production in pharmacogenomic alleles affected by interethnic variability.
Yamoune S et al.
Biochimica Et Biophysica Acta. General Subjects, 2024
Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population.
Zhang LQ et al.
Heliyon, 2024